Deana Mohr-Haralampieva, Steve Kappenthuler, Marcus Droege
{"title":"通过组织工程学治疗压力性尿失禁","authors":"Deana Mohr-Haralampieva, Steve Kappenthuler, Marcus Droege","doi":"10.1038/s44222-024-00246-6","DOIUrl":null,"url":null,"abstract":"Stress urinary incontinence (SUI), a frequently underdiagnosed condition that mainly affects women, lacks effective and long-term treatment options. MUVON Therapeutics has developed a tissue-engineered advanced therapy medicinal product for the treatment of SUI, based on autologous cells, which is being tested in a phase II clinical study — a challenging development effort.","PeriodicalId":74248,"journal":{"name":"Nature reviews bioengineering","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treating stress urinary incontinence by tissue engineering\",\"authors\":\"Deana Mohr-Haralampieva, Steve Kappenthuler, Marcus Droege\",\"doi\":\"10.1038/s44222-024-00246-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Stress urinary incontinence (SUI), a frequently underdiagnosed condition that mainly affects women, lacks effective and long-term treatment options. MUVON Therapeutics has developed a tissue-engineered advanced therapy medicinal product for the treatment of SUI, based on autologous cells, which is being tested in a phase II clinical study — a challenging development effort.\",\"PeriodicalId\":74248,\"journal\":{\"name\":\"Nature reviews bioengineering\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature reviews bioengineering\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/s44222-024-00246-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature reviews bioengineering","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s44222-024-00246-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
压力性尿失禁（SUI）是一种常被漏诊的疾病，主要影响女性，但却缺乏长期有效的治疗方案。MUVON Therapeutics 公司已开发出一种基于自体细胞的组织工程先进疗法药物产品，用于治疗 SUI，目前正在进行 II 期临床研究测试，这是一项极具挑战性的开发工作。
Treating stress urinary incontinence by tissue engineering
Stress urinary incontinence (SUI), a frequently underdiagnosed condition that mainly affects women, lacks effective and long-term treatment options. MUVON Therapeutics has developed a tissue-engineered advanced therapy medicinal product for the treatment of SUI, based on autologous cells, which is being tested in a phase II clinical study — a challenging development effort.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
